General Information of Drug (ID: DMK209P)

Drug Name
1-(2-isopropylphenoxy)-3-morpholinopropan-2-ol Drug Info
Synonyms CHEMBL1083668; 1-(2-isopropylphenoxy)-3-morpholinopropan-2-ol; Oprea1_740178; AC1N31P0; 1-morpholin-4-yl-3-(2-propan-2-ylphenoxy)propan-2-ol; BDBM50318979
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
4080436
TTD Drug ID
DMK209P

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Propranolol DM79NTF Angina pectoris BA40 Approved [2]
Epinephrine DM3KJBC Acute asthma CA23 Approved [3]
Norepinephrine DMOUC09 Alopecia ED70 Approved [4]
Atenolol DMNKG1Z Angina pectoris BA40 Approved [5]
Acebutolol DM0TI4U Hypertension BA00-BA04 Approved [5]
Metoprolol DMOJ0V6 Acute coronary syndrome BA41 Approved [5]
Timolol DM3NXRU High blood pressure BA00 Approved [6]
Isoproterenol DMK7MEY Atrioventricular block Approved [7]
Betaxolol DM6EUL5 Hypertension BA00-BA04 Approved [8]
Sotalol DML60TN Sinus rhythm disorder BC9Y Approved [9]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Mirabegron DMS1GYT Overactive bladder GC50.0 Approved [10]
Trihexyphenidyl DMB19L8 Dystonia 8A02 Approved [11]
Amosulalol DML8QSZ Hypertension BA00-BA04 Approved [12]
Bopindolol DMIFYLX Hypertension BA00-BA04 Approved [13]
Mepindolol DMUDWP9 Angina pectoris BA40 Approved [14]
Rimiterol DMA47C6 Asthma CA23 Approved [15]
Bitolterol DMK6XAV Chronic obstructive pulmonary disease CA22 Approved [16]
Nipradilol DMA65ER Angina pectoris BA40 Approved [17]
Vibegron DMFR201 Overactive bladder GC50.0 Approved [18]
ONO-2506 DMCA2PJ Stroke 8B20 Phase 2/3 [19]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Indacaterol DMQJHR7 Chronic obstructive pulmonary disease CA22 Approved [20]
Formoterol DMSOURV Allergic asthma CA23.0 Approved [21]
Salbutamol DMN9CWF Acute asthma CA23 Approved [22]
Arformoterol DMYM974 Chronic obstructive pulmonary disease CA22 Approved [23]
Isoproterenol DMK7MEY Atrioventricular block Approved [7]
Salmeterol DMIEU69 Allergic asthma CA23.0 Approved [24]
Clenbuterol DMCKYZ5 Chronic breathing disorder 7A4Z Approved [25]
Ritodrine DM4V6RL Premature labour JB00 Approved [26]
Olodaterol DM62B78 Chronic obstructive pulmonary disease CA22 Approved [27]
Fenoterol DMIP3ZV Asthma CA23 Approved [28]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Adrenergic receptor beta-1 (ADRB1) TTR6W5O ADRB1_HUMAN Inhibitor [1]
Adrenergic receptor beta-2 (ADRB2) TT2CJVK ADRB2_HUMAN Inhibitor [1]
Adrenergic receptor beta-3 (ADRB3) TTMXGCW ADRB3_HUMAN Inhibitor [1]

References

1 A vHTS approach for the identification of beta-adrenoceptor ligands. Bioorg Med Chem Lett. 2010 Jun 1;20(11):3399-404.
2 Beta-blockers in the treatment of hypertension: are there clinically relevant differences Postgrad Med. 2009 May;121(3):90-8.
3 Adrenergic activation of electrogenic K+ secretion in guinea pig distal colonic epithelium: involvement of beta1- and beta2-adrenergic receptors. Am J Physiol Gastrointest Liver Physiol. 2009 Aug;297(2):G269-77.
4 Impact of exogenous beta-adrenergic receptor stimulation on hepatosplanchnic oxygen kinetics and metabolic activity in septic shock. Crit Care Med. 1999 Feb;27(2):325-31.
5 Prediction and experimental validation of acute toxicity of beta-blockers in Ceriodaphnia dubia. Environ Toxicol Chem. 2005 Oct;24(10):2470-6.
6 Topical dorzolamide 2%/timolol 0.5% ophthalmic solution: a review of its use in the treatment of glaucoma and ocular hypertension. Drugs Aging. 2006;23(12):977-95.
7 Current therapeutic uses and potential of beta-adrenoceptor agonists and antagonists. Eur J Clin Pharmacol. 1998 Feb;53(6):389-404.
8 beta-adrenergic enhancement of brain kynurenic acid production mediated via cAMP-related protein kinase A signaling. Prog Neuropsychopharmacol Biol Psychiatry. 2009 Apr 30;33(3):519-29.
9 beta(2)-adrenoceptors are critical for antidepressant treatment of neuropathic pain. Ann Neurol. 2009 Feb;65(2):218-25.
10 Nat Rev Drug Discov. 2013 Feb;12(2):87-90.
11 Obesity: pathophysiology and clinical management. Curr Med Chem. 2009;16(4):506-21.
12 Effects of amosulalol, a combined alpha 1- and beta-adrenoceptor-blocking agent, on ischemic myocardial energy metabolism in dogs. J Pharm Sci. 1993 Mar;82(3):291-5.
13 Effect of propranolol, alprenolol, pindolol, and bopindolol on beta 2-adrenoceptor density in human lymphocytes. J Cardiovasc Pharmacol. 1986;8 Suppl 6:S70-3.
14 Pharmacological studies on the intrinsic sympathomimetic activity of the beta-adrenoceptor antagonist mepindolol. Arzneimittelforschung. 1986 May;36(5):811-3.
15 Comparison of the beta2-adrenoceptor selectivity of rimiterol, salbutamol and isoprenaline by the intravenous route in man. Br J Clin Pharmacol. 1975 Feb;2(1):41-8.
16 Bitolterol mesylate: a beta-adrenergic agent. Chemistry, pharmacokinetics, pharmacodynamics, adverse effects and clinical efficacy in asthma. Pharmacotherapy. 1985 May-Jun;5(3):127-37.
17 Actions of nipradilol (K-351), a new alpha- and beta-adrenoceptor blocker, on the rabbit portal vein. Jpn J Pharmacol. 1984 Aug;35(4):359-69.
18 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
19 FR149175, a beta 3-adrenoceptor-selective agonist, is a possible therapeutic agent for non-insulin-dependent diabetes mellitus. Jpn J Pharmacol. 1997 May;74(1):109-12.
20 Emerging drugs in chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2009 Mar;14(1):181-94.
21 Long-acting beta2-agonists for chronic obstructive pulmonary disease patients with poorly reversible airflow limitation. Cochrane Database Syst Rev. 2002;(3):CD001104.
22 Potential of beta2-adrenoceptor agonists as add-on therapy for multiple sclerosis: focus on salbutamol (albuterol). CNS Drugs. 2002;16(1):1-8.
23 Arformoterol tartrate in the treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease. Drugs Today (Barc). 2009 Jan;45(1):3-9.
24 Pharmacogenetic tests in asthma therapy. Clin Lab Med. 2008 Dec;28(4):645-65.
25 Postischemic brain injury is attenuated in mice lacking the beta2-adrenergic receptor. Anesth Analg. 2009 Jan;108(1):280-7.
26 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
27 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
28 Functional alpha1- and beta2-adrenergic receptors in human osteoblasts. J Cell Physiol. 2009 Jul;220(1):267-75.